Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients

被引:0
|
作者
Zhang, Xiaomin [1 ]
Yang, Jieli [1 ]
Chen, Sai [1 ]
Liu, Chang [1 ]
Wang, Zhenhua [1 ]
Ren, Hefei [1 ]
Zhou, Lin [1 ]
机构
[1] Naval Med Univ, Shanghai Changzheng Hosp, Dept Lab Med, 415 Fengyang Rd, Shanghai 200003, Peoples R China
基金
芬兰科学院; 中国国家自然科学基金;
关键词
Hypertension; Multiple myeloma; Progression-free survival; Risk stratification; BLOOD-PRESSURE; PARATHYROID-HORMONE; CANCER; RISK; CELLS; INTERLEUKIN-6; INFLAMMATION; MEDICATIONS; CALCIUM;
D O I
10.1007/s11239-022-02653-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Approximately 31% of patients diagnosed with multiple myeloma (MM) have pre-existing hypertension, but its effects on patient survival have not been investigated. We collected data from 228 newly diagnosed patients with MM and found that 71 (31.1%) had pre-existing hypertension. The impact of pre-existing hypertension on MM patients was determined by evaluating progression-free survival (PFS). Kaplan-Meier analyses revealed a significantly lower PFS in the pre-existing hypertension group than their non-hypertensive counterparts (median 22.6 vs 34.8 months, respectively). The multivariable Cox proportional hazards model showed that pre-existing hypertension was an independent risk factor for PFS reduction in MM patients. Moreover, the risk of disease progression in MM patients with pre-existing hypertension was higher than in non-hypertension comparator patients (hazard ratio 1.735, 95% confidence interval 1.261-2.387). In MM patients with pre-existing hypertension, Kaplan-Meier analyses found that those with a higher risk of hypertension had a significantly shorter PFS than those with lower risk (median 19.3 vs 25.4 months, respectively). However, multivariate Cox regression analysis showed that the risk stratification of hypertension was not an independent risk factor for poor PFS in MM patients with pre-existing hypertension. Our study demonstrates that pre-existing hypertension was significantly associated with a lower PFS in newly diagnosed MM patients.
引用
收藏
页码:542 / 549
页数:8
相关论文
共 50 条
  • [31] High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma
    Wang, Liang
    Wang, Jing-hua
    Liu, Wen-jian
    Wang, Wei-da
    Wang, Hua
    Chen, Xiao-qin
    Geng, Qi-rong
    Lu, Yue
    Xia, Zhong-jun
    ANNALS OF HEMATOLOGY, 2017, 96 (12) : 2079 - 2088
  • [32] Autologous Hematopoietic Stem Cell Transplant in Multiple Myeloma: Plerixafor Mobilization and Progression-Free Survival
    Dutari, Pilar
    Musso, Veronica
    Colombo, Evelyn
    Sol Jarchum, Maria
    Alvarez Bollea, Maria
    Mas, Emilia
    Laura Rizzi, Maria
    Lavarda, Marcelo
    Minoldo, Daniel
    Jarchum, Gustavo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S289 - S289
  • [33] Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT
    Ho, Christine M.
    McCarthy, Philip L.
    Wallace, Paul K.
    Zhang, Yali
    Fora, Ahmad
    Mellors, Patrick
    Tario, Joseph D.
    McCarthy, Benjamin L. S.
    Chen, George L.
    Holstein, Sarah A.
    Balderman, Sophia R.
    Cao, Xuefang
    Paiva, Bruno
    Hahn, Theresa
    BLOOD ADVANCES, 2017, 1 (15) : 1056 - 1066
  • [34] Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma
    Ludwig, Heinz
    Milosavljevic, Dejan
    Berlanga, Oscar
    Zojer, Niklas
    Huebl, Wolfgang
    Fritz, Veronique
    Harding, Stephen
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (03) : 295 - 301
  • [35] Endocan expression is correlated with poor progression-free survival in patients with pancreatic neuroendocrine tumors
    Lin, Liang-Yu
    Yeh, Yi-Chen
    Chu, Chia-Huei
    Won, Justin G. S.
    Shyr, Yi-Ming
    Chao, Yee
    Li, Chung-Pin
    Wang, Shin-E
    Chen, Ming-Huang
    MEDICINE, 2017, 96 (41)
  • [36] Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients
    Zangari, Maurizio
    Barlogie, Bart
    Cavallo, Federica
    Bolejack, Vanessa
    Fink, Louis
    Tricot, Guido
    BLOOD COAGULATION & FIBRINOLYSIS, 2007, 18 (07) : 595 - 598
  • [37] Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities
    Guman, Tomas
    Sykora, Jan
    BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, 2024, 125 (01): : 9 - 11
  • [38] Serological Response to Vaccination after Autologous Transplantation for Multiple Myeloma Is Associated with Improved Progression-Free and Overall Survival
    Merz, Almuth M. A.
    Merz, Maximilian
    Zhang, Yali
    Stecklein, Kathryn
    Pleskow, Jordan
    Chen, George L.
    Buck, Dennis A.
    Mohammadpour, Hemn
    Herr, Megan M.
    Elshoury, Amro
    Hillengass, Jens
    McCarthy, Philip L.
    Hahn, Theresa
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (03): : 245.e1 - 245.e8
  • [39] 1q21+is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study
    Gao, Shuang
    Dong, Fei
    Yang, Ping
    Chen, Yingtong
    Wang, Yanfang
    Wang, Jing
    Shi, Yanyan
    Jing, Hongmei
    ANNALS OF HEMATOLOGY, 2024, 103 (06) : 1979 - 1987
  • [40] Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma
    Chee, Adrian
    Low, Michael S.
    Vilcassim, Shahla
    Gregory, Gareth P.
    Gilbertson, Michael
    Ratnasingam, Sumita
    Grigoriadis, George
    Fedele, Pasquale L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (05) : 739 - 741